Forum Archive Index - March 2000

["David Reid" <aspex@ix.net.nz>]

GPG just goes to prove that being in the UK market does not guarantee performance.

Now Sir Ron bemoans the fact that his share price is too low.

 

Now on another tack entirely to show why I am in the UK market.

This is not a tip but look at Provalis (PRO in UK /PVLS on NASDAQ)

Bought by me at 20p and fell to 13p (poor timing) now 35.75p and $US 7.50 on NASDAQ at the close which is equivalent to 97p UK.

Why did I buy? They were a struggling pharma developer in UK with a top product (oral insulin, I believe). They decided to give up on their own marketing team and farm out this.

Why is the price rising?

This comment from 16/3/99 announcement to the market.

MacrulinTM - oral formulation of insulin for treatment of diabetes The development programme for this product is progressing to schedule and is maintaining its promise.  A series of clinical research studies is underway to confirm a commercial dosage form of the product from single dose studies in Type I diabetics and an initial multiple dose one-day study in Type 2 diabetics.  These studies will allow assessment of the likely clinical utility and indications to underpin the commercial potential of MacrulinTM.  The dosing is now complete and data are undergoing analysis. The preliminary analysis of the first Clamp study in Type I patients has demonstrated unequivocal evidence that the revised formulation of the product can deliver biologically active insulin in man through intestinal absorption. We expect to issue a further statement regarding this study in the second quarter of 1999.